Replies to post #43217 on Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The Strange Story Of Remdesivir, A Covid Drug That Doesn’t Work

https://www.forbes.com/sites/jvchamary/2021/01/31/remdesivir-covid-coronavirus/

NIH sponsored study made Remdesivir COVID-19 approval possible.

https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19

Injury to the liver of the COVID-19 patients???

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386240/

ZYESAMI/RLF-100/AVIPTADIL is safe and has decades of studies/research. The FDA/CDC/NIH are slow-walking the safe/AMAZING NEUROPEPTIDE!!!

VIP is known to target the VPAC1 receptor of the alveolar type II (ATII) cell and protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. In addition, VIP prevents apoptosis, blocks cytokines, lowers TNFa levels, reverses CD4/CD8 ratio, and reduces cough and dyspnea in nonclinical and clinical studies.

Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and primarily concentrated in the lungs. In addition, VIP has been shown in more than hundreds of peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation says the Company.

Because of its lack of toxicity and low cost of manufacture compared to proprietary biologics, VIP may be uniquely attractive to those focused on global countermeasures against COVID-19, says the Company.

https://www.precisionvaccinations.com/vaccines/zyesami-aviptadil-covid-19-therapeutic